Scalp Cooling Therapy for Chemotherapy-Induced Hair Loss in Asian Patients with Breast or Gynecological Cancers – A Tertiary Institution Experience

    March 2024 in “ Research Square (Research Square) ”
    Victor Lee, Jerold Loh, Hui Fu, Raghav Sundar, Belinda Tan, Lee Moy Chong, Hui Ying Lin, Lay Ching Ong, Nisha Visvanadan, Samuel Guan Wei Ow, Andrea Li‐Ann Wong, Gloria Chan, Siew Eng Lim, Yi Wan Lim, David S.P. Tan, Yvonne Ang, Joan Choo, Matilda Lee, Natalie Ngoi, Soo Chin Lee, Richard G. Paxman, Anna Parker, Yee Mei Lee, Joline Si Jing Lim
    Image
    Studysummary In this study, scalp cooling therapy was found to be well tolerated and effective at improving hair preservation for Asian women with breast or gynecological cancers undergoing certain chemotherapy regimens, particularly weekly paclitaxel, compared to historical controls. Our plain-language summary of this paper — not a Tressless recommendation.
    Scalp cooling therapy (SCT) was evaluated in 83 Asian women with breast or gynecological cancers undergoing chemotherapy at a tertiary institution. The study, conducted over 18 months, involved 510 SCT cycles using the Paxman system. Results showed that 94% of patients found SCT comfortable. Hair preservation success was highest in patients receiving weekly paclitaxel (76.7%) and lower in those on a 3-weekly paclitaxel regimen (50%) or anthracycline and cyclophosphamide (5.3%). Overall, SCT was well tolerated and significantly improved hair preservation or regrowth compared to historical controls.
    Discuss this study in the Community →